Navigation Links
SoluBest Appoints Michael Sheckler, MBA, as CEO
Date:9/10/2008

TEL AVIV, Israel, Sept. 10 /PRNewswire/ -- SoluBest Ltd., a privately held, clinical stage developer of a novel solubilizing technology, has appointed Michael Sheckler, MBA, as CEO. Mr. Sheckler brings over 25 years of pharmaceutical experience to SoluBest.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080910/NEW068LOGO )

Mr. Sheckler began his career with the Ross Division of Abbott Laboratories, selling nutritional and pharmaceutical products. During his time there, he served in a variety of sales roles, winning numerous awards. As a market research analyst, Mr. Sheckler was responsible for the market assessment and product launch plans for several line extensions.

Mr. Sheckler left Ross in 1999 to join Bespak, Inc., a drug delivery technology company, where he held several roles of increasing responsibility. As Head of Marketing for the newly created Nasal Drug Delivery business, he was instrumental in launching the business stream, assessing and growing new business opportunities in the U.S., and developing and implementing the launch and marketing plans for new products.

Upon leaving Bespak, Mr. Sheckler joined Intranasal Technology, Inc, a Kentucky-based nasal drug delivery company as Director of Business Development where he successfully created and implemented a business development and marketing communications strategy positioning the company for its entry into the nasal analgesia market.

Prior to joining SoluBest, Mr. Sheckler served as Vice President of Business Development at Javelin Pharmaceuticals. During his tenure, he realized annual savings of $350M through recognizing and negotiating a new contract manufacturing agreement and strengthened a successful $32M fundraiser through serving an integral role in investor conferences and road shows.

Mr. Sheckler graduated from Indiana University and obtained his MBA from The Fuqua School of Business at Duke University in Durham, North Carolina. He has been an Editorial Advisor for the journal, "Specialty Pharma," and has chaired and spoken at numerous industry conferences. Mr. Sheckler has authored several articles which have been published in industry magazines.

"SoluBest has successfully advanced its technology in a critically important area of medicine. This promises to enhance patient outcomes through innovative and improved drug delivery. Now, with Michael Sheckler joining our talented team, we are confident that his added value will allow us to realize that promise in short order," said SoluBest Board Chairman Ronnie Hershman, M.D.

"I'm excited to have the opportunity to lead SoluBest to the next level of growth and commercialization. I share the passion of our Board and shareholders to bring our state-of-the-art technology to the pharmaceutical market in order to provide solubility-enhancing formulations for our partners' currently marketed and pipeline molecules," commented Mr. Sheckler.

About SoluBest

SoluBest is a clinical stage company developing proprietary nanoformulation-based improvements of existing compounds and compounds in development.

The company applies its Solumer(TM) technology to poorly soluble or insoluble drugs which have not achieved their therapeutic potential due to delivery and/or compliance deficiencies.

The Company's proprietary solubilization technology is versatile and is widely applicable to numerous off-patent (or soon to be off-patent) drugs and new chemical entities (NCE's).

A significant advantage of the technology stems from its use of readily available equipment for a process consisting of a few simple steps - making scale-up safe, robust, rapid and inexpensive.

For more information, visit http://www.solubest.com.


'/>"/>
SOURCE SoluBest Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Affitech Appoints Dr. Keith McCullagh as Chairman
3. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
4. Algenol Biofuels Appoints Chief Science Officer
5. Axial Biotech appoints new Vice President of Strategic Initiatives
6. Insulet Appoints Bill Arthur as Vice President of Business Development
7. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
8. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
9. Landauer, Inc. Appoints Two New Members to Board of Directors
10. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
11. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... ... of Strategic Planning. His extensive background in consulting, development and marketing make ... marketing and differentiation consulting, business strategy development, new product marketing and global ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... announced that the stock market news outlet had initiated coverage on Interpace ... that screens and identifies exposure, progression and risk analysis from specific cancers ...
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture Development™ (VIC™), ... of directors. This addition continues to strengthen and diversify VIC’s board. , "We ... Chairman. “He is a highly accomplished business executive with a broad range of experience ...
(Date:7/18/2017)... ... July 18, 2017 , ... Nanomedical Diagnostics, a ... announces the launch of a new NTA biosensor chip for use with its ... the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. , “Recombinant proteins ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
Breaking Biology News(10 mins):